

Registered number: 57125
Charity number: CHY 6100
CRA number: 20010270

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)
DIRECTORS' REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

ASTHMA SOCIETY OF IRELAND

CONTENTS

| | Page |
|---------------------------------------|-------------|
| Directors and Other Information | 1 |
| Directors' Report | 2-14 |
| Directors' Responsibilities Statement | 15 |
| Independent Auditor's Report | 16-18 |
| Statement of Financial Activities | 19 |
| Balance Sheet | 20 |
| Statement of Cash Flows | 21 |
| Notes to the Financial Statements | 22-38 |

ASTHMA SOCIETY OF IRELAND
DIRECTORS AND OTHER INFORMATION

| | |
|--|--|
| Directors | David Clancy, Chair (resigned on 18/05/2022) Ciaran McGloin, Interim Chair (18/05/2022) Lorna Jennings Vincent Butterly Ciara Kelly (resigned 21/07/2022) Sharon Edge Marcus Butler James Dunny Liam Osborne (resigned 01/07/2022) Catherine Lonergan Hilary Gormley Henry Minogue (resigned 28/11/2022) Deirdre Ardagh (appointed 11/08/2022) Aine Nolan (appointed 11/08/2022) Maitiú Ó Faoláin (appointed 18/08/2022) |
| Company Secretary | Ciaran McGloin (resigned 30/09/2022) Vincent Butterly (appointed 30/09/2022) |
| Chief Executive Officer | Sarah O'Connor (resigned 04/11/2022) |
| Interim Chief Executive Officer | Eilís Ní Chaithnía (since 17/08/2022) |
| Director Emeritus | Anne Robinson |
| Company registered number | 57125 |
| Charity registered number | CHY 6100 |
| Charities Regulatory Authority number | 20010270 |
| Registered office | 3rd Floor 42-43 Amiens Street Dublin 1 |
| Independent auditor | Mazars Chartered Accountants & Statutory Audit Firm Harcourt Centre Block 3 Harcourt Road Dublin 2 |
| Principal Bankers | Bank of Ireland 2 College Green Dublin 2 AIB Bank George's Street Dun Laoghaire Co Dublin |
| Solicitors | Sherwin O'Riordan 74 Pembroke Road Ballsbridge Dublin 4 |

ASTHMA SOCIETY OF IRELAND
DIRECTORS' REPORT
for the year ended 31 December 2022

The Directors present their annual report and audited financial statements for the year ended 31 December 2022.

DIRECTORS AND COMPANY SECRETARY

The Directors and Secretaries who served during the year are set out on page 1.

PRINCIPAL ACTIVITIES AND OBJECTIVES

The Asthma Society of Ireland ("Asthma Society", "the Society" or "ASI") is the voice of asthma in Ireland. We champion change to prevent asthma deaths. We communicate about asthma to ensure it is taken seriously as a health challenge. We support with services for all people with asthma, empowering them to control the condition and providing health promotion programmes. We learn together and collaborate with healthcare, research and education professionals to improve our understanding of how asthma works and how to combat it.

Our vision is that everyone in Ireland with asthma lives a full life, symptom free. Our mission is to eliminate asthma deaths and transform the lives of people with asthma.

BUSINESS REVIEW AND FINANCIAL RESULTS

2022 was a year of transition for the Society, involving a whole-of-organisation review of our income generation strategies and activities, resulting in the adoption of our new Financial Resilience and Sustainability Strategy and Tactical Plan by the non-Executive Board of Directors in July 2022.

The Society's efforts throughout 2022 to increase statutory core funding were successful, with the HSE reaffirming the organisation's crucial contribution to asthma healthcare in Ireland through increased investment. This investment is aimed at facilitating the transition to the Financial Resilience and Sustainability Strategy and the delivery of the Tactical Plan.

The Society's net surplus in 2022 was €11,052 (2021 deficit €132,200), accomplished primarily through the support of its statutory funders, as well as contributions from corporate funders and the fundraising initiatives undertaken by members of the public. The decision was made to limit activities in pursuit of restricted income streams and to, instead, focus on boosting the organisation's capacity to secure unrestricted income.

Other welcome developments included the adoption of our Beating Breathlessness digital services programme, previously funded under the Sláintecare Integration Fund, by the HSE under a new annual Grant Aid Agreement. The HSE further acknowledged the valuable work of the organisation by confirming its intention to continue funding our Adviceline and Beating Breathlessness programmes beyond 2022.

The Society was approved for renewed funding under the Scheme to Support National Organisations (SSNO) for a further three years and secured €100,000 in corporate donations for the first of a three-year Advocacy and Research Programme on Severe Asthma (€50,000 from GSK and €50,000 from AstraZeneca).

While the overall contraction of the Society's finances and staffing capacity, which began in 2021, continued into 2022, the Board and Senior Executive worked closely and effectively to maintain stability and continue to deliver and, indeed, grow our patient services. The Patient Services Team was restructured and expanded from one to three programmatic roles, with our nurses and physiotherapist delivering a 14% increase in Adviceline calls, a total of 5,027 WhatsApp interventions to 519 people and webinars delivered every 6-8 weeks with an average of 250 people registered and 130 attendees per webinar. Each service, assessed in part through customer satisfaction surveys, scored highly in terms of likelihood to be recommended and impact on asthma knowledge base.

The team drove outreach among healthcare professionals – GPs, practice and respiratory nurses, consultants and integrated care teams – to promote our free patient support services and resources, as a means of enhancing patient education and reducing unscheduled healthcare visits arising from uncontrolled asthma.

The Society was not immune to the economic and labour market conditions, however, with retention and recruitment of staff impacted. 2022 was a year of rebuilding, with the Board of Directors and Senior Executive working closely to lay the foundations for financial and operational stability. Contraction of the workforce was used as an opportunity to reimagine the operating structure of the Society and a recruitment process was initiated in Q3 to build the team accordingly. Four posts were filled in that period, with more recruitment initiated and rolling into 2023.

ASTHMA SOCIETY OF IRELAND
DIRECTORS' REPORT
for the year ended 31 December 2022

Changes in key personnel in 2022 included most notably, the appointment of Ciaran McGloin, non-Executive Director and Chair of the Audit, Risk and Finance Committee of the Board, as Interim Chair in May 2022, and of Eilís Ní Chaithnía, Deputy CEO and Advocacy and Research Manager as Interim CEO in August 2022, following resignation of the former postholders. The Board established a temporary Transition Committee of three Board Members to support this interim period, including guiding strategic priorities. Eilís Ní Chaithnía was appointed as CEO of the Asthma Society on 17th April 2023.

Gross income for the year was made up as follows:

| | 2022 | 2021 |
|---|----------------|----------------|
| | € | € |
| HSE and other Statutory Funding | 630,616 | 444,617 |
| Community fundraising, donations, membership and other income | 85,946 | 152,803 |
| Corporate sponsorship and charitable trust income | 21,496 | 156,937 |
| Investment income | 12 | - |
| Total | 738,070 | 754,357 |

The Society's expenditure in 2022 was €727,018 (2021: €886,557). Taking into account the cost of fundraising, the Society's net surplus in 2022 was €11,052 (2021 net deficit: €132,200).

The Society has received confirmation of annual funding for the Adviceline and Beating Breathlessness programmes from the HSE for 2023. The Asthma Society has received a transfer of €184,932 core funding for 2023 from the HSE in March 2023.

RESERVES POLICY

The Board recognises the need to hold reserves to ensure the financial stability of the Society and to protect the Society from the risk of significant future loss of income. In particular, the Board recognises the need to acquire new funding streams and to pursue further unrestricted revenue streams.

The Society has relied on its reserves in recent years, particularly in 2021. Part of the Society's recovery plan as outlined in the Financial Resilience and Sustainability Strategy will be working to re-build the level of unrestricted funds, particularly in 2024 and annually thereafter.

Annually, the Board reviews the level of activities of the Society to determine the minimum level of reserves needed to meet its minimum funding policy. The Executive of the Society monitors the reserves on an ongoing basis and the Board formally reviews its reserves policy on an annual basis to ensure it remains appropriate for the financial stability of the Society, or more frequently when required.

It is also the policy of the Society to hold sufficient reserves to fund its activities and maintain the quality of its services for a minimum period of 2 months, plus redundancy costs. For the current year, this equates to approximately €200,183. The current balance of unrestricted funds of €221,536 (2021: €130,571) meets this requirement.

ACHIEVEMENTS AND PERFORMANCE

The Society continued to adapt in 2022 to meet changed patient needs as a result of COVID-19. Despite lower capacity, key functions – finance, patient services, health promotion and advocacy – were maintained. The Executive team worked successfully to maintain standards in operations, to nurture existing relationships and to build relationships with new stakeholders.

The organisation refined its focus to correspond with its reduced resources, while maintaining ambition and clarity of purpose, and keeping the patient at the centre of our work. As per the strategic direction of the Board, the Executive continued to prioritise, above all, the key patient-facing services and the ongoing sustainability and development of the organisation.

ASTHMA SOCIETY OF IRELAND
DIRECTORS' REPORT
for the year ended 31 December 2022

ACHIEVEMENTS AND PERFORMANCE (continued)

The Society continued to adapt to meet changed patient needs as a result of COVID-19 in 2022. Despite lower capacity, key functions – finance, patient services, health promotion and advocacy – were maintained. The Executive team worked successfully to maintain standards in operations, to nurture existing relationships and to build relationships with new stakeholders.

The organisation refined its focus to correspond with its reduced resources, while maintaining ambition and clarity of purpose, and keeping the patient at the centre of our work. As per the strategic direction of the Board, the Executive continued to prioritise, above all, the key patient-facing services and the ongoing sustainability and development of the organisation.

PILLAR ONE: WE CHAMPION CHANGE

GOAL 1: To draft and implement an Asthma Deaths Strategy aiming to halve asthma deaths from the current level by 2025 and stop asthma deaths by 2030.

A strategic decision was taken to adjust this strategic goal slightly to reflect the revised view that an Asthma Deaths Strategy should be drafted and owned by the State and that the Asthma Society would advocate for a consultation process leading to the publication of an Asthma Deaths Strategy, including an implementation plan and commitment to review. The Asthma Society raised this matter with the new Clinical Lead of the National Clinical Programme Respiratory (NCPR) on his appointment.

The Society also determined that key to its own goal to reduce asthma deaths, it was essential that we continue to promote appropriate use of medication, including inhaler technique, as well as pushing for the full implementation of the HSE's new End-to-end Model of Care for Asthma. The Asthma Society, as a show of endorsement for the Model of Care, supported our volunteer Asthma Ambassador – an expert by experience – Sarah Darcy to speak at the launch of the publication, invited by the NCPR. Sarah raised importance of standardisation of care and the need for an implementation plan for the Model of Care, identifying relevant actors, attributing responsibility for actions and setting out an implementation timeline to demonstrate momentum and accountability to asthma patients and healthcare professionals across Ireland.

The Society continued to promote the use of preventer inhalers and advise against overuse of Oral Corticosteroids with the development and dissemination of two information videos for patients and GPs. We held an 'Ask the Doctor' webinar with GP Dr. Dermot Nolan, attended by 74 patients, during which 29 questions were answered on the question of asthma management and medication adherence. The recording of the webinar was disseminated to the 205 people who registered, as well as posted to our website.

In the lead up to Asthma Awareness Week (1-7 May) 2022, we conducted a membership survey on children and asthma. A national media campaign was conducted with 13,284,156 opportunities to see, hear or read about the Asthma Awareness Week campaign not including social media or ezine reach. As of 9 May, there were 146 pieces of coverage, including 3 television pieces, 7 national print, 10 regional print, 4 national radio, 58 regional radio, 56 online and 8 trade pieces.

As part of this campaign, the CEO and DCEO met Minister of State at the Department of Education with special responsibility for Special Education and Inclusion Josepha Madigan in Leinster House to highlight the special needs of children with asthma in schools. In particular, the risk to the health and lives of children with asthma posed by the absence of nationwide training in asthma management and unsuitable regulation of salbutamol storage and administration in organisations were highlighted. The Minister committed to supporting the organisation to tackle the gaps in asthma care in education settings and follow up communication has been conducted with the Minister to this end.

GOAL 2: To build awareness of the financial cost of asthma among key health decision makers and to effectively lobby for better management of State spending on asthma, to reduce the burden on individual patients.

The Asthma Society, in 2021 and 2022, engaged with the HSE to seek additional core funding to support the organisation in its transition to its new Financial Resilience and Sustainability Strategy and Tactical Plan. Core to

ASTHMA SOCIETY OF IRELAND
DIRECTORS' REPORT
for the year ended 31 December 2022

this engagement was the communication of the particular and substantial value the organisation brings to the State and to those who require additional services and supports. Through the provision of free, expert guidance and education to people with asthma and their carers, the Asthma Society represents a partial solution to the substantial cost to patients of accessing care, as well as to costly and avoidable healthcare utilisation (particularly unscheduled hospital visits) as a result of uncontrolled asthma.

In conjunction with the cost of asthma medication and care and in our work calling for the regulation of the sale and use of solid fuels, the Asthma Society highlighted the impact of the cost of living crisis, inflation and spiralling fuel prices on the affordability of burning clean fuels in the home. These factors can result in medically vulnerable people being forced to choose between burning fuels that release pollution directly into their homes and communities or living in cold damp conditions, both circumstances that pose high risk to people with asthma or those who may be predisposed to asthma.

Our advocacy and media work on Clean Air throughout 2022 – including submissions we made to government – highlighted the heightened risk of exposure to air pollutants to those on lower incomes, those living in substandard accommodation, homeless populations and Travellers, populations with disproportionate rates of asthma.

The impact of health inequalities and, in particular, the financial burden of managing their disease on persons with asthma and their families is planned as a priority focus for 2023 and beyond.

GOAL 3: To create an awareness of severe asthma and its impact on quality of life and to lobby all relevant agencies to ensure equality of access to necessary treatments and healthcare.

In Q4 2021, the Asthma Society began reaching out to funders to seek financial support for the roll-out of the first of a three-year substantive programme of work to highlight gaps in severe asthma healthcare and treatment and the obstacles to accessing this treatment. By Q3 2022, €100,000 had been secured for the programme and, in Q4, a dedicated Programme Coordinator was recruited, with a view to delivering the programme in full in 2023. While seeking funding, the Society contributed to formalised discussions among key healthcare actors in Ireland to promote a patient-centred approach.

GOAL 4: To change Irish society to create a more asthma-friendly environment in homes, schools, clubs and workplaces and in our wider environment.

If we are to reach the Asthma Society's vision of everyone with asthma living a full life, we must ensure that our surroundings are not exacerbating asthma symptoms, are responsive to our medical needs and are not *causing* new cases of asthma. Throughout 2022, we took a multi-pronged approach, collaborating with a variety of actors to drive this strategic goal forward. We are very proud to be part of the LIFE EMERALD Project led by the Environmental Protection Agency (EPA), which is creating a national 3-day air quality forecast for Ireland, near real-time mapping of air pollutants throughout the country and historical maps of air pollutants. All of which will lead to improved management of Ireland's air quality. Our role in this project is to highlight the impact of poor air quality on public health. The Deputy CEO presented on this topic at the EPA's annual Air Quality Event in 2022 and worked with project partners in the design of an air quality digital display in Temple Street Hospital.

As members of the Climate and Health Alliance, we ensured respiratory needs and risks of poor air quality were reflected in the Alliance's relevant submissions to government and communications. We also endorsed the Community Law and Mediation's submission to the government's consultation on the Clean Air Strategy, as well as making a submission to the Department of Environment, Climate and Communications ourselves. Minister Eamon Ryan highlighted the calls made by the Asthma Society on banning smoky fuels during Leader's Questions in the Dáil, highlighting the risks they pose to children with asthma.

The Deputy CEO sat on the Medical and Clinical Services Working Group for the Consultation on the draft HSE Climate Action and Sustainability Strategy 2022-2050, in which greener devices were a focus. We conducted a number of media communications on the subject of air quality throughout 2022 in national press and broadcast.

Our now annual Asthma Safe School Programme engages with principals, teachers, SNAs and children to prevent asthma deaths. The programme uses webinars, first aid training, and digital school packs to improve awareness of asthma management in the school setting. The aim is to train one teacher per school in PHECC (Pre Hospital

ASTHMA SOCIETY OF IRELAND
DIRECTORS' REPORT
for the year ended 31 December 2022

Emergency Care) approved and certified basic life support and administration of Salbutamol for emergency treatment of adults and children with an acute asthma attack. It also enables school staff to identify what to do in the case of an asthma attack, to encourage schools to provide a supportive environment for students with asthma, to create better public awareness of the 5 Step Rule and how to recognize and manage an asthma attack. The Society was granted funding from the HSE National Lottery Fund for programme delivery in three CHO areas in 2022. The Programme is due to be rolled out from January to May 2023.

PILLAR TWO: WE COMMUNICATE ABOUT ASTHMA

GOAL 5: To create better public awareness of the 5 Step Rule, how to recognise and manage an asthma attack.

The Society has traditionally relied on newsletters, e-zines, graphics and gifs, practical tips and advice via social media and the website to communicate regularly and effectively with the public in recent years, showing increased engagement levels year-on-year and having a positive impact on awareness and uptake of the Society's services. The Asthma Society has not had any internal staffing working in the communications function in 2022 and the day-to-day awareness building has been impacted as a result, and Strategic Goals 5 & 6 were combined to ensure all our awareness campaigns highlighted the risk of asthma deaths and signposted, where possible, to the 5-Step Rule.

GOAL 6: To communicate with the wider public about asthma, its management, its challenges. To do so, we must create memorable campaigns that last, kick-starting behaviour change among people with asthma.

Asthma Awareness Week 2022 had the overarching objective to highlight the experience of uncontrolled asthma in children, and to communicate how quality of life can be transformed with improved self-management. A substantive survey was conducted to gauge impact of asthma on children and understand better how children and their family can be supported with their asthma. The survey asked parents and guardians about their children's experience of having asthma during COVID-19, in particular in educational setting. The findings were extremely concerning, with parents reporting heightened anxiety among themselves and their children, misinformation among educators of the symptoms of asthma versus COVID-19, the alarming rate of missed school days among children with asthma (often required by the school in response to their asthma-related cough) and reports of some parents forgoing buying medication or GP visits due to financial constraints. We highlighted the free expert supports and advice available via the Asthma Adviceline and WhatsApp messaging services as key solutions to supporting enhanced asthma management at home and in schools. The Society also focussed on telling the stories of people with asthma and their families through print and broadcast media interviews and video and digital events, including stories on the experience of losing a close family member to asthma. Findings from the survey were issued in a press release nationally as well as separate regional releases to garner optimum coverage. The campaign was carried across national print, radio and television, as well as trade publications and regional and online media. The campaign achieved a total of 151 pieces of coverage and 13,392,497 opportunities to see, hear or read about Asthma Awareness Week. The CEO was featured on Newstalk news bulletins and was interviewed on Newstalk Breakfast Briefing on the morning of World Asthma Day. Fearne Tivy (aged 9) was interviewed about her experience of having asthma on RTE News2Day. Opinion editorials by Asthma Society Nurse Specialist Ruth Morrow appeared in Irish Pharmacy News and Hospital Professional News about asthma in childhood. The Irish Times, Irish Independent and The Evening Herald featured Asthma Ambassador Colet Murphy highlighting the challenge of living with severe asthma.

The Society also highlighted our Clean Air calls for improved air quality in Ireland over Asthma Awareness Week 2022, achieving 80 pieces of coverage across national television and radio, and in online, trade and regional media.

On World Asthma Day 2022, DPD Ireland launched its Air is for Life video series. We partnered with the parcel delivery firm to create a video about the impact of air pollution on people with asthma. The videos were used during the launch of a digital dashboard that allows Dublin residents and those visiting Dublin to check up-to-the-minute air pollution (PM2.5) levels data across the city.

The Asthma Society's Asthma award-winning Safetycare campaign, launched in 2019 and supported by AstraZeneca, is focused on educating the public and healthcare professionals about the overuse of Oral Corticosteroids and bringing key behavioural changes around asthma management and best practices to the attention of patients and their carers, healthcare professionals and health policy decision-makers. In 2022, we

ASTHMA SOCIETY OF IRELAND
DIRECTORS' REPORT
for the year ended 31 December 2022

focused more specifically on highlighting among GPs the health risks of overprescribing Oral Corticosteroids, with two videos created and disseminated across various channels.

Our Winter Wellness Campaign, which began in December 2021, ran into Q1 2022 with a number of key media pieces featuring key messages to empower people with asthma to improve their disease awareness, ability to control their symptoms and their confidence in engaging with their healthcare. We did this by building awareness amongst our members and the general public of the challenge in keeping well with asthma during the winter months.

PILLAR 3: WE SUPPORT WITH SERVICES

Goal 7: To help people with asthma through our services to create and follow their Asthma Action Plan, as a key tool to combat asthma deaths.

The Asthma Society currently delivers two HSE-funded patient services programmes, delivered by expert nurses that provide free-of-charge self-management education and support to people with asthma and their support networks. Our Asthma Adviceline is a free call-back service delivered by our nurses to people with asthma in Ireland and to their support networks. It provides up-to-date, expert information and advice on how to manage asthma and to get the most out of interactions with asthma healthcare services. The Asthma Adviceline was established in 1982 and is funded by the HSE since 2016, along with COPD Adviceline. The COPD Adviceline is a collaboration between the Asthma Society of Ireland, COPD Support Ireland and the HSE. It is delivered by a COPD nurse and a physiotherapist and provides up-to-date, reliable and accurate information over the phone to people with COPD and their support networks on living well with COPD.

Across the two Advicelines, the nurse and physiotherapist team delivered 3,873 phone appointments in total (up from 3,735 in 2021), 2,978 of which were with our Asthma Adviceline and 896 with the COPD Adviceline. In response to calls to our services or offices, 732 asthma management resources and 94 COPD resources were distributed in 2022 by the Society. The most requested resource (156 copies) was our Asthma Attack Card, featuring the 5-Step Rule to follow during an asthma emergency.

In May 2020, the Asthma Society launched its digital patient services programme, which was funded by the Sláintecare Integration Fund until June 2022, when it was approved for long-term funding by the HSE. One of the services delivered through the programme is an asthma & COPD WhatsApp messaging service. Respiratory nurses deliver a confidential self-management 'chat' service. The nurses provide tailored information, advice and resources to support service users and signpost to healthcare services, where required. The service also delivers regular health promotion webinars on matters of seasonal or thematic interest to people with asthma and COPD.

Service learnings indicate that once-off usage of the WhatsApp messaging service is effective but builds in impact when patients return and use it repeatedly and many patients do use it regularly. 519 unique contacts were made to our nurses delivering the WhatsApp messaging service in 2022, with a total of 5,027 nurse interventions delivered. 48 per cent of contacts were made on the individuals own behalf, 42 per cent were made on behalf of a child with asthma, with the remaining contact made on another's behalf. When asked whether they would recommend the service to others, 96 per cent of service users confirmed they would.

Alongside the WhatsApp messaging service, the Society delivers health promotion webinars to patients, carers and healthcare professionals, with expert respiratory healthcare professional panels providing in-depth information on key aspects of asthma and COPD management. A facilitated Q&A section between the healthcare professional and the attendees is included in every webinar.

We delivered a series of 6 webinars for people with asthma/COPD in 2022. These webinars involve experts in the field of respiratory medicine with our nurses also contributing to them. The webinars provide an ongoing relationship with existing patients that avail of our services (Adviceline and WhatsApp nurse messaging service) and promote our services to a wider audience. In total, there was 1,560 registrations, with an average per webinar of 260 registered. A total of 726 attended or watched back, averaging 121 views per webinar, with an average of 32 attendee questions answered by panellists per webinar.

ASTHMA SOCIETY OF IRELAND
DIRECTORS' REPORT
for the year ended 31 December 2022

In post-webinar surveys, 100% of respondents indicated that they would recommend the WhatsApp messaging service to a family member, friend or colleague and 75% felt their confidence in managing their condition increased since using this service.

GOAL 8: To ever improve our new and existing health promotion programmes and support services, working closely with the HSE and other partners, ensuring that they are excellent and impactful, and especially assisting those who are socially excluded.

The Asthma Society's Medical Advisory Group, led by Consultant in Respiratory Medicine in St. Vincent's Hospital Dr. Marcus Butler, are a panel of committed respiratory experts who oversee the clinical accuracy of our resources and information disseminated through our services. Our nursing and physiotherapy team attend 6-weekly Learning Team Meetings where thematic experts lead information sessions and the continuous quality standards assessments are conducted collectively.

In 2022, a Clinical Risk Audit Group was set up within the Society, advised by our Medical Director, to actively monitor and review our patient services and ensure we are meeting and maintaining the clinical standards. A key focus of the Group was our application to the Helpline Partnership Accreditation, which must be renewed every three years and certifies best practice and quality standards in helplines such as ours.

The Society placed significant emphasis on engagement and collaboration with healthcare professionals and their representative bodies in 2022. In order to promote and enhance our patient services, the team reached out to healthcare professionals across primary and secondary care, facilitated by the National Clinical Programme Respiratory. The Asthma Society met regularly with the Programme's newly appointed Clinical Lead for Asthma, Dr Stanley Miller, to ensure our patient services activities were aligned with the Integrated Care initiative of the HSE. With the endorsement of the Clinical Programme, the Society developed and disseminated a 'referral pad' to healthcare professionals engaging with respiratory patients, which allowed for ease of signposting to our WhatsApp and Adviceline services where additional education on disease management was deemed beneficial.

PILLAR FOUR: WE LEARN TOGETHER

GOAL 9: To deepen our relationships and collaboration with all relevant healthcare and scientific professionals, helping them to become a fulcrum for change in patients, ultimately creating the best healthcare landscape and outcomes for people with asthma.

We recommenced our in-person presence at key conferences and events in 2022, with promotional stalls and Asthma Society representatives in attendance at the Anáil Respiratory Nurse Association conference, the ICGP conference, the Medical Practice Society conference, the Irish Thoracic Society's conference, as well as at the Bealtaine festival in Galway, and Healthy Ireland 'In Your Library' event.

We conducted webinars for GPs on medcafe, an education hub for GPs, made a presentation to National CDM Respiratory Support group on ASI services and regularly attended the HSE's Service-user Chronic Disease Hub CHO9.

We published articles in various medical trade publications, Professional Hospital News, Irish Pharmacy News, Practice Matters, IPGNEA nurse journal in which our services have been promoted. Future publications will continue to promote our services also.

GOAL 10: To undertake and facilitate research to improve our understanding of asthma in Ireland and its potential treatment and management.

The Society supported a Spark Innovation Programme project led by Sandra Green in the Mater Hospital, which produced a toolkit for healthcare professionals on inhalers and carbon footprint. The tool consists of a brief guide to being a "green prescriber", a device choice and carbon footprint table and an evidence document. The Asthma Society endorsed the toolkit and will disseminate and promote its launch. Our patient services nurses were briefed on this toolkit and a discussion was facilitated on the potential for action on the environment by healthcare actors.

PILLAR 5: WE BUILD CAPACITY

ASTHMA SOCIETY OF IRELAND
DIRECTORS' REPORT
for the year ended 31 December 2022

GOAL 11: To diversify, deepen and sustain our future finances by growing our statutory, corporate, philanthropic and public fundraising.

2022 was the inaugural year of the Asthma Society's Take a Breath campaign, which invited people across Ireland to 'take a breath' for the 380,000 men, women and children living with asthma over St. Patrick's Weekend and raise funds for their support services. Through a number of planned events throughout the weekend, the public were encouraged to join the Asthma Society and participate. These included a sunset 'In Memory' walk, led by Comedian and Asthma Ambassador, Rory O'Connor, in the Phoenix Park at 5pm on Saturday 19th to remember all those who lost their life to asthma and COVID-19, Yoga in the Phoenix Park on Sunday 20th, led by park HIIT. The Asthma Society challenged the public to take on their own challenge – be that taking an icy plunge at the Forty-Foot, cycling the Greenway with friends, taking on the Conor Pass, or simply catching up with friends over a coffee – however they choose to 'Take a Breath'. They were asked to do so for those living with asthma and to set up a fundraising page or simply donate on asthma.ie. However, the public chose to 'Take a Breath', they were encouraged to tag the Asthma Society on social media and use the hashtag #TakeaBreath. The campaign resulted in 108 pieces of coverage and 11,111,650 opportunities to see, hear or read about the 'Take a Breath' fundraising appeal. In terms of social media there was a reach of 332,115 (unique views) across all four social channels and an engagement rate of 5.66%.

The Society also continued to deliver its Breathe Easy Workplace Wellness Programme to interested corporate partners, including Spectrum Life and EY. The Programme, a nurse-led health promotion initiative that aims to improve health outcomes and to support the wellbeing of all employees, through the provision of educational tools, direct to employee expert support, and self-management strategies to cultivate a supportive and healthy environment where employees can thrive. With the Breathe Easy Programme, the Asthma Society can enable organisations to deliver the highest standard in workplace wellbeing in an accessible and effective way.

With the support of the Community Foundation of Ireland, the Society commissioned support in developing a Financial Resilience and Sustainability Strategy and Tactical Plan, which was adopted by the non-Executive Board of Directors in July 2022. The strategy focuses on the diversification of unrestricted income streams across individual membership, community events and corporate partnerships/sponsorship to establish a model of income generation that is not overly reliant on any one source and significantly reduces the organisation's requirement for core Statutory funding in the longer term. The strategy sets out income targets, KPIs, and target ROI across these income streams and over three years. Significant outreach was undertaken to enhance diversification of our private income streams through prospective corporate, trust and foundation and Statutory donors.

GOAL 12: To substantially grow our ability by developing our team, services, systems and ways of thinking, delivering nationally and impactfully for patients by leading in the charity sector.

A process of prioritisation was undertaken by the Executive in conjunction with the Board throughout 2021 and 2022 with the aim of protecting key patient-facing services and bolstering our finances, prioritising these above all other proposed activities. The full Asthma Society team worked extraordinarily hard to maintain standards, to continue to provide services and to continue our health promotion and advocacy impacts, before, during and after these challenging organisational changes. In a year when it was not easy to be on a stretched team, the Asthma Society's employees and Board were exceptionally dedicated.

Within the constraints acknowledged above, and with a significantly reduced team, the team's dedication to helping and supporting patients, carers and healthcare professionals to improve asthma management and save lives was exemplary. The Society wants to commend the professionalism, hard work and resilience of its team.

ASTHMA SOCIETY OF IRELAND
DIRECTORS' REPORT
for the year ended 31 December 2022

CORPORATE FUNDERS 2022

The Asthma Society would like to thank the following Corporate Funders for their support in 2022:

Astra Zeneca
Environmental Protection Agency
Central Bank of Ireland
GSK
The Wheel

STRUCTURE, GOVERNANCE AND MANAGEMENT

GOOD GOVERNANCE AND TRANSPARENCY

The Asthma Society of Ireland made a compliant return in 2022 with "The Charities Governance Code" issued by the Charities Regulatory Authority in Ireland.

Our accounts and financial reports are compliant with Statement of Recommended Practice (SORP).

Our nurse-led services are compliant with the Code of Professional Conduct and Ethics for Registered Nurses and Registered Midwives and our Asthma Adviceline service is fully accredited by the Helplines Partnership (this accreditation was renewed for three years in early 2019). With staffing capacity challenges, it was not possible for the Patient Services team to complete the extensive re-accreditation process in early 2022 and this will be finalised in 2023.

To actively demonstrate openness, transparency and integrity to our beneficiaries and donors, the Asthma Society aims to operate to the Triple Lock Standards of transparent reporting, good fundraising and governance. The Asthma Society continued to work at the required level for full adherence to this sectoral standard for the entirety of 2022 but has not yet formally submitted the formal application for Triple Lock accreditation as a result of reduced staffing capacity.

The Board of Directors met seven times in 2022, which reflected the need in 2022 to adapt the organisation's fundraising, activities and operations as a result of the COVID-19 pandemic. The Directors have responsibility for appointing the Chief Executive Officer who has decision making powers in relation to a range of day to day decisions. Sarah O'Connor served as Chief Executive Officer to 4 November 2022, with Eilís Ní Chaithnía appointed Interim Chief Executive Officer on 16 August 2022.

The Board is supported by its Medical Advisory Group (MAG), its Audit, Risk and Finance Committee (ARFC) and its Fundraising and Communications Committee (FCC). The Society also benefits from occasional supports offered by its Independent Air Advisory Panel to support its work on its Clean Air advocacy and awareness work – this panel is made up of highly qualified scientists and researchers with expertise in air quality and its impact on our environment and our health.

The Society offers a one-to-one briefing with the CEO for all newly recruited Directors. Each new Director is also given a Directors Handbook and briefing pack, which includes bios of other board members, recent board minutes (and sub-committee minutes and terms of reference where relevant), the Memorandum and Articles of Association of the organisation, the Staff Handbook, a copy of the Society's strategy, among other key briefing materials. Board members are asked to sign a code of conduct.

The Society periodically reviews the salaries of its CEO, its management team and of its team members. In 2019, the Society had an external HR consultancy review the relevant salary scales in use by the organisation and changes were made at that point in time, in conjunction with the ARFC and Remuneration Committee.

The Society published its Five-Year Strategy in May 2020, *Stopping Asthma Deaths in Ireland, 2020-2025*, with an ultimate goal of ending asthma deaths by 2030, and has been prioritising its work in 2022 based on the strategic direction this document provides. Where the Society has not been in a position to undertake programmatic or project work, the underlying principles of the strategy have been central to choosing the most appropriate service and activity mix.

ASTHMA SOCIETY OF IRELAND
DIRECTORS' REPORT
for the year ended 31 December 2022

CONSTITUTION

The Society updated its membership and its Memorandum and Articles of Association in 2020 to meet with best practice corporate governance standards, as set out by the CRA under its guidelines.

The charity was founded in 1973 and registered as a company limited by guarantee in 1976. The liability of members is limited as defined in the Company's Constitution and shall not exceed €5 in the event of a winding up or dissolution of the Company.

The principal office of the Society is 3rd Floor, 42 - 43 Amiens Street, Dublin 1. The Company's registered number is 57125, its Charities Regulator number is 20010270 and its charity registration number is CHY 6100. Governance and management structures are set out in the Constitution.

The Society is governed by its Board of Directors, which includes representation from a broad range of stakeholders including people with asthma, carers of people with asthma, the medical profession, communications, legal and financial experts. The Directors are appointed to terms of office that comply with the Constitution of the Society. The term of office is generally three years, but Directors may be reappointed to serve two further terms.

FUTURE DEVELOPMENTS

A recruitment plan to expand the team, approved by the Board of Directors in July 2022, was initiated in Q4 and will continue throughout the first half of 2023. It is expected that the staff body, excluding those delivering the services, will have tripled by June 2023. The Society will also conduct open recruitment competitions for a new CEO and new voluntary Chair in 2023, with a view to developing and launching a new impact-focused strategic plan that will be contextualised within the post-COVID healthcare landscape, shifting political environment and cost-of-living crisis.

The Asthma Society will also mark its 50th anniversary in 2023 with a range of activities recognising the many accomplishments of the organisation, the developments in asthma care over that period and the challenges facing people with asthma and their families still to address.

We will continue to grow and promote our services, focusing particularly on those most vulnerable to asthma attacks and poor lung health, and build engagement with healthcare professionals and new and existing respiratory healthcare providers. We will highlight the gaps in care and the need for increased State investment in asthma care, while supporting the National Clinical Programme Respiratory to optimise its Chronic Disease Management Programme and the Integrated Care Strategy which have the already begun to transform asthma care for the better.

The Asthma Society piloted the Asthma Safe Schools programme in 2021 in four CHOs. In 2022, the Society has succeeded in securing funding in three CHOs for our Asthma Safe Schools programme. A number of individual fundraisers also supported the roll-out of this programme by undertaking fundraising in their local area. This programme will be delivered in the first half of 2023. The society also secured €100,000 for our Severe Asthma Programme. It has recruited the coordinator and the programme will be delivered throughout 2023.

The Asthma Society's Asthma Awareness Week 2023 will focus on the impact of the cost of living crisis on people with asthma.

The Society will continue to advocate for increased core statutory funding for the supports and services it provides to the 380,000 patients with asthma.

Impact of COVID-19

The impact of COVID-19 on the Society's abilities to generate unrestricted income to support programmes has meant that some activities were not continued in 2022 and will have to be assessed on an annual basis until sufficient funding is available to run them.

The Society has prided itself on taking a collaborative approach across all programmatic areas in recent years and has worked to retain that approach in 2022. However, without ongoing funding to support some activities, operations were scaled back at the end of 2020. The Society has identified funding opportunities across advocacy and

ASTHMA SOCIETY OF IRELAND
DIRECTORS' REPORT
for the year ended 31 December 2022

awareness which may provide staffing capacity and programmatic funding to allow for increased work across respiratory organisations in the future, where such applications are successful.

The Society has been assessing its ongoing programmatic mix in 2022. It is prudent for the Society to prioritise the programmes it undertakes to ensure it has sufficient resourcing, funding and impact to best support patients, their carers and healthcare professionals.

PRINCIPAL RISKS AND UNCERTAINTIES

The Board of Directors has assessed the major risks to which the Society is exposed.

Risk management approach:

The Society maintains a risk appetite document and a risk register. The Audit, Risk and Finance Committee ("ARFC") are responsible for the oversight of the maintenance of both. The risk register was updated in March 2022 and is a regular standing item on all ARFC agendas. A whole of organisation and always-on approach is applied to risk in the Society.

The new Patient Services Manager has, in Q3 2022, commenced work on a re-appraisal of the Society clinical risk audit of the patient services, which will be supported by the Medical Advisory Group (particularly the Medical Director), a working group of the Society's nursing team, and a clinical risk external expert. This will feed into the Society's organisational re-accreditation with the Helplines Partnership.

The principal risks and uncertainties facing the Society are as follows:

Maintaining financial stability and sustainability:

The work of the Society requires funding. Accordingly, the main risk facing the Society in achieving its strategy is its ability to reverse the trend of 2021 and H1 2022, and to grow income back to levels seen in 2020, which will allow for the necessary rebuilding of reserves and create certainty around team capacity and key programme delivery.

The Society prepares budgets and cash flow forecasts, which are reviewed on a regular basis in conjunction with its management accounts. Depending on the results, the Directors, where necessary, take appropriate action. Monthly accounts and the related analysis and controls are a key output for the Society. The appointment of a new Finance and Compliance Manager in January 2023 brought about change to provide greater insight into the long-term financial management of the Society for the Board and CEO, including more forensic cash flow monitoring and improved projections and corresponding insight into the financial position of the Society.

The Society has developed a Financial Resilience and Sustainability Strategy, aiming to deepen, diversify and grow income, with a particular focus on unrestricted corporate donations, successful trust and foundation applications, membership income, programmes generating income and a high profile digital Take A Breath fundraising annual campaign, showing strong year-on-year growth. Parallel to this, the Society worked in a strategic manner to broaden the statutory core funding available to the organisation, with key successes across SSNO funding renewal, programmatic funding certainty for Beating Breathlessness and securing €250,000 core funding from the HSE.

Staff recruitment and retention:

The Society achieves its results through its CEO and staff. If the Society is to achieve its objectives, the CEO and other staff must build close and effective relationships where they can deliver on the Society's mission together. The team restructuring and retention challenge meant that continuity and organisational memory was affected through 2022. While for this extended period of time, the organisation has been unable to recruit key vacancies, the Q4 2022 – Q2 2023 recruitment project positions the Society well to resolve this challenge. The Directors are satisfied that, with this project progressing, there will be adequate staff recruitment for the organisation's current and future needs.

ASTHMA SOCIETY OF IRELAND
DIRECTORS' REPORT
for the year ended 31 December 2022

Significantly reduced staffing capacity:

The Society's Board, Executive and team worked very hard to bring a focus on prioritisation to bear on the programmes, focussing on delivery of patient supports and service delivery and excellence across Adviceline and Beating Breathlessness (WhatsApp and webinars) as primary priorities in 2022. To deliver strongly on these state funded activities with agreed service level agreements, the Society has in 2022 reduced its commitments in other respects across advocacy, awareness and research. The Q4 2022 – Q2 2023 recruitment project has allowed for a return to these activities in a controlled, costed and agreed manner in 2023.

Operational Excellence:

The Directors are satisfied that the system of internal controls and procedures provides reasonable assurance of the safeguarding of assets, the maintenance of proper accounting records, and the reliability of the financial information, particularly in light of proposed recruitment and rebuilding of the staffing structure in Q4 2022 – Q2 2023. An organisational administrative processes review is preceding and running alongside this recruitment project to ensure operational excellence continues with new personnel being onboarded.

Medical oversight:

The Society seeks to ensure that the advice it offers to patients and their carers is up-to-date and appropriate. Accordingly, the Society has access to a Medical Advisory Group to assess and guide the Society's approach to minimise the risk that our stakeholders receive advice that is not best practice. The Society, in particular, also gains extensive insight, technical advice and guidance from its Medical Director, Dr. Marcus Butler.

ACCOUNTING RECORDS

The measures taken by the Directors to ensure compliance with the requirements of Sections 281 to 285 of the Companies Act 2014, with regard to the keeping of accounting records, are the employment of appropriately qualified accounting personnel and the maintenance of computerised accounting systems. The company's accounting records are maintained at the company's registered office.

POST BALANCE SHEET EVENTS

There have been no events since the balance sheet date, which necessitate revision of the figures included in the financial statements or inclusion of a note thereto.

POLITICAL CONTRIBUTIONS

There were no political contributions which require disclosure under the Electoral Act 1997.

ASTHMA SOCIETY OF IRELAND
DIRECTORS' REPORT
for the year ended 31 December 2022


STATEMENT ON RELEVANT AUDIT INFORMATION

In the case of each of the persons who are directors at the time this report is approved in accordance with Section 332 of the Companies Act 2014:

- so far as each director is aware, there is no relevant audit information of which the company's statutory auditors are unaware, and
- each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's statutory auditors are aware of that information.

INDEPENDENT AUDITOR

In accordance with Section 382(2) of the Companies Act 2014, the auditors, Mazars, will continue in office.



Ciaran McGloin
Director



Vincent Butterly
Director

Date: 25 October 2023

ASTHMA SOCIETY OF IRELAND
DIRECTORS' RESPONSIBILITIES STATEMENT
for the year ended 31 December 2022

The Directors are responsible for preparing the Directors' report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have elected to prepare the financial statements in accordance with the Companies Act 2014, FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' issued by the Financial Reporting Council and the Statement of Recommended Practice (Charities SORP (FRS 102)), issued by the Charity Commission for England and Wales, the Charity Commission for Northern Ireland and the Office of the Scottish Charity Regulator. Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the Company as at the end of the financial year, and the results of the Company for the financial year, and otherwise comply with the Companies Act 2014.


In preparing those financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The Directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and income and expenditure of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' report comply with the Companies Act 2014 and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in Ireland governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

On behalf of the Board of Directors


Ciaran McGloin
Director


Vincent Butterly
Director

Date: 25 October 2023

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF
ASTHMA SOCIETY OF IRELAND**

Report on the audit of the financial statements

Opinion

We have audited the financial statements of Asthma Society of Ireland ('the Company'), which comprise the Statement of Financial Activities, the Balance Sheet, Statement of Cash Flows, and notes to the Company financial statements, including the summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish law and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland.

In our opinion, the accompanying financial statements:

- give a true and fair view of the assets, liabilities and financial position of the Company as at 31 December 2022, and of its results for the year then ended;
- have been properly prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report.

We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF
ASTHMA SOCIETY OF IRELAND (CONTINUED)**

Other information

The directors are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2014

In our opinion, based on the work undertaken in the course of the audit, we report that:

- the information given in the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements;
- the directors' report has been prepared in accordance with applicable legal requirements;
- the accounting records of the Company were sufficient to permit the financial statements to be readily and properly audited; and
- the financial statements are in agreement with the accounting records.

We have obtained all the information and explanations which, to the best of our knowledge and belief, are necessary for the purposes of our audit.

Matters on which we are required to report by exception

Based on the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified any material misstatements in the directors' report.

The Companies Act 2014 requires us to report to you if, in our opinion, the requirements of any of Sections 305 to 312 of the Act, which relate to disclosures of directors' remuneration and transactions are not complied with by the Company. We have nothing to report in this regard.

Respective responsibilities***Responsibilities of directors for the financial statements***

As explained more fully in the directors' responsibilities statement out on page 15 the directors are responsible for the preparation of the financial statements in accordance with the applicable financial reporting framework that give a true and fair view, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF
ASTHMA SOCIETY OF IRELAND (CONTINUED)**

Respective responsibilities (continued)


Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Irish Auditing and Accounting Supervisory Authority's website at: http://www.iaasa.ie/getmedia/b2389013-1cf6-458b-9b8f-a98202dc9c3a/Description_of_auditors_responsibilities_for_audit.pdf. This description forms part of our auditor's report.

The purpose of our audit work and to whom we owe our responsibilities

Our report is made solely to the Company's members, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.



Aedín Morkan
for and on behalf of Mazars
Chartered Accountants & Statutory Audit Firm
Harcourt Centre, Block 3
Harcourt Road
Dublin 2

Date: 27 October 2023

ASTHMA SOCIETY OF IRELAND

**STATEMENT OF FINANCIAL ACTIVITIES (Including income and expenditure account)
for the year ended 31 December 2022**

| | Unrestricted funds 2022 € | Restricted funds 2022 € | Total funds 2022 € | Total funds 2021 € |
|-----------------------------------|------------------------------------|----------------------------------|-----------------------------|-----------------------------|
| Income from: | | | | |
| Donations and legacies | 4 | 90,226 | 17,216 | 107,442 |
| Charitable activities | 5 | - | 630,616 | 630,616 |
| Investments | 6 | 12 | - | 12 |
| Total income | 90,238 | 647,832 | 738,070 | 754,357 |
| Expenditure on: | | | | |
| Raising funds | 7 | 8,179 | 22,041 | 30,220 |
| Charitable activities | 8 | 41,510 | 655,288 | 696,798 |
| Total expenditure | | 49,689 | 677,329 | 727,018 |
| Net income / (expenditure) | | 40,549 | (29,497) | 11,052 |
| Transfer between funds | 19 | 50,416 | (50,416) | - |
| Net movement in funds | | 90,965 | (79,913) | 11,052 |
| Reconciliation of funds: | | | | |
| Total funds at 1 January | 19 | 130,571 | 89,311 | 219,882 |
| Total funds at 31 December | 19 | 221,536 | 9,398 | 230,934 |


There were no other recognised gains or losses in the current or prior year other than those included in the Statement of Financial Activities. All income and expenditure derive from continuing activities. The notes on pages 22 to 38 form part of these financial statements.


ASTHMA SOCIETY OF IRELAND

BALANCE SHEET
as at 31 December 2022

| | Note | 2022 € | 2021 € |
|-------------------------------------|------|----------------|----------------|
| FIXED ASSETS | | | |
| Tangible assets | 14 | 15,272 | 22,337 |
| CURRENT ASSETS | | | |
| Stocks | 15 | 1,212 | 1,212 |
| Debtors | 16 | 209,400 | 71,273 |
| Cash and cash equivalents | | 453,170 | 285,902 |
| | | 663,782 | 358,387 |
| CREDITORS | | | |
| Amounts falling due within one year | 17 | (448,120) | (160,842) |
| NET CURRENT ASSETS | | | |
| | | 215,662 | 197,545 |
| TOTAL NET ASSETS | | | |
| | | 230,934 | 219,882 |
| FUNDS | | | |
| Unrestricted funds | 19 | 221,536 | 130,571 |
| Restricted funds | 19 | 9,398 | 89,311 |
| TOTAL FUNDS | | | |
| | | 230,934 | 219,882 |

The financial statements were approved and authorised for issue by the Directors and signed on their behalf by:


Ciaran McGloin
Director


Vincent Butterly
Director

Date: 25 October 2023

The notes on pages 22 – 38 form part of these financial statements.

ASTHMA SOCIETY OF IRELAND
STATEMENT OF CASH FLOWS
for the year ended 31 December 2022

| | Note | 2022 € | 2021 € |
|---|------|----------------|-----------|
| Cash flows from operating activities | | | |
| Net income / (expenditure) for the year | | 11,052 | (132,200) |
| Adjustments for: | | | |
| Depreciation of tangible fixed assets | 14 | 7,065 | 7,569 |
| Deposit interest income | 6 | (12) | - |
| Increase in debtors | | (138,127) | (11,173) |
| Increase in creditors | | 287,278 | 16,520 |
| Net cash generated by / (used in) operating activities | | 167,256 | (119,284) |
| Cash flows from investing activities | | | |
| Deposit interest income | 6 | 12 | - |
| Net cash generated by investing activities | | 12 | - |
| Net increase /(decrease) in cash and cash equivalents | | 167,268 | (119,284) |
| Cash and cash equivalents at the start of the year | | 285,902 | 405,186 |
| Cash and cash equivalents at the end of the year | | 453,170 | 285,902 |

The notes on pages 22 - 38 form part of these financial statements.

ASTHMA SOCIETY OF IRELAND
NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 December 2022

1. GENERAL INFORMATION

Asthma Society of Ireland ("the Charity") is a Company Limited by Guarantee incorporated in Ireland with a registered office at 3rd Floor, 42-43 Amiens Street, Dublin 1, Ireland and its company registration number is 57125.

These financial statements comprising the Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flows and the related notes constitute the financial statements of the Asthma Society of Ireland for the financial year ended 31 December 2022. The nature of the Charity's operations and its principal activities are set out in the Directors' Report on page 2.

Asthma Society of Ireland meets the definition of a public benefit entity under FRS 102.

Statement of compliance

The financial statements have been prepared in accordance with "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (FRS 102). The financial statements have also been prepared in accordance with the Statement of Recommended Practice (SORP) (FRS 102) "Accounting and Reporting by Charities".

Currency

The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. ACCOUNTING POLICIES

The following accounting policies have been applied consistently to all years in dealing with items which are considered material in relation to the financial statements.

2.1 Basis of preparation of financial statements

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention modified to include certain items at fair value. The financial reporting framework that has been applied in their preparation is the Companies Act 2014, FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' issued by the Financial Reporting Council and the Statement of Recommended Practice (Charities SORP (FRS102)) as published by the Charity Commission for England and Wales, the Charity Commission for Northern Ireland and the Office of the Scottish Charity Regulator which are recognised by the UK Financial Reporting Council (FRC) as the appropriate bodies to issue SORPs for the charity sector in the UK. Financial reporting in line with SORP is considered best practice for charities in Ireland.

The Directors consider that the adoption of the SORP requirements is the most appropriate accounting to properly reflect and disclose the activities of the organisation.

ASTHMA SOCIETY OF IRELAND

NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2022

2. ACCOUNTING POLICIES (continued)

2.2 Income

All income is recognised in the Statement of Financial Activities where there is entitlement, receipt is probable, and the amount can be measured with sufficient reliability. The following specific policies are applied to categories of income:

Donations and legacies: Voluntary income including donations, gifts and legacies are recognised where there is entitlement, receipt is probable, and the amount can be measured with sufficient reliability. Such income is only deferred when the donor specifies that the grant or donation must only be used in future accounting periods or the donors have imposed conditions which must be met before the Charity has unconditional entitlement.

Donations received from individuals and companies using online fundraising platforms to raise funds are recognised when the funds are registered on the online platform.

Legacy income is recognised in the accounting period in which it is received or when it is probable that the legacy will be received, and the value of the legacy can be measured reliably. In these circumstances, if the legacy income has been received post year end, and the personal representatives have agreed to the amount thereof prior to the year end, the income can be recognised.

Assets donated under bequests or otherwise are included in the Statement of Financial Activities at their value to the Charity on the date of receipt.

Income from Charitable Activities: Grants from public authorities and other agencies in Ireland are credited to the Statement of Financial Activities in the year to which they relate. Grants received towards capital expenditure are credited to the Statement of Financial Activities when received or receivable whichever is earlier. Grants are recognised when there is evidence of entitlement and their receipt is probable. Grant income is deferred where the Charity is restricted by specific performance related conditions that are evident in the grant agreement, where there is a specification of a time period that limits the Charity's ability to spend the grant until it has performed that activity related to the specified time period and when there are specific terms or conditions within the agreement that have not been met and are not within the control of the Charity.

Fundraising income: Fundraising income is credited to the Statement of Financial Activities in the year in which it is receivable by the Charity.

Investment income: Income earned on funds held on deposit is treated as unrestricted income and is credited when earned. Interest received on the Charity's investments is recorded as income in the year in which it is earned under the effective interest rate method.

Deferred income: Deferred income consists of grants received in advance which will be recognised upon fulfilment of the related conditions.

ASTHMA SOCIETY OF IRELAND
NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2022

2. ACCOUNTING POLICIES (continued)

2.3 Expenditure

Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is reported as part of the expenditure to which it relates:

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities.

Charitable expenditure comprises those costs incurred by the Charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Support costs arise from those functions that assist the work of the Charity but do not directly undertake charitable activities. Costs are charged to each service and activity in proportion to expenditure, which is considered to reflect estimated benefits received.

Governance costs include those costs associated with meeting the constitutional and statutory requirements of the Charity and include the audit fees, costs of legal advice for Directors and costs linked to the strategic management of the Charity including the cost of Directors' meetings.

2.4 Fund accounting

Restricted funds

Restricted funds represent grants, donations and sponsorships received which can only be used for particular purposes specified by the donors or sponsorship programmes binding on the Directors. Such purposes are within the overall aims of the Charity.

Unrestricted funds

Unrestricted funds include general funds and designated funds and represent amounts which are expendable at the discretion of the Directors in furtherance of the objectives of the Charity. Such funds may be held in order to finance working capital or capital expenditure.

2.5 Tangible fixed assets and depreciation

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

| | | |
|-----------------------|---|-------------------|
| Fixtures and fittings | - | 20% straight line |
| Computer equipment | - | 33% straight line |

The company's policy is to review the remaining useful economic lives and residual values of tangible fixed assets on an ongoing basis and to adjust the depreciation charge to reflect the remaining estimated useful economic life and residual value.

Fully depreciated tangible fixed assets are retained in the cost of tangible fixed assets and related accumulated depreciation until they are removed from service. In the case of disposals, assets and related depreciation are removed from the financial statements and the net amount, less proceeds from disposal, is charged or credited to the Statement of Financial Activities.

ASTHMA SOCIETY OF IRELAND
NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2022

2. ACCOUNTING POLICIES (continued)

2.6 Stocks

Stocks are valued at the lower of cost and net realisable value after provisions for obsolete and slow-moving stocks.

2.7 Trade and other debtors

Trade and other debtors are initially measured at cost, which is normally the transaction price, and are subsequently measured at amortised cost less impairment, where there is objective evidence of impairment.

2.8 Cash and cash equivalents

Cash and cash equivalents include cash on hand, demand deposits and other short-term highly liquid investments with original maturities of three months or less.

2.9 Trade and other creditors

Trade and other creditors are measured at transaction price, unless payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate. In this case the arrangement constitutes a financing transaction, and the financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

2.10 Operating leases

Leases that do not transfer all the risks and rewards of ownership are classified as operating leases. Payments under operating leases are charged to the Statement of Financial Activities on a straight-line basis over the period of the lease.

2.11 Taxation

The entity is a registered charity (number CHY6100). All of its activities are exempt from direct taxation.

VAT recovered under the VAT Compensation Scheme is recognised as income in the Statement of Financial Activities upon receipt.

ASTHMA SOCIETY OF IRELAND

NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2022

2. ACCOUNTING POLICIES (continued)

2.12 Employee benefits

Short term benefits

Short term benefits, including holiday pay and other similar non-monetary benefits are recognised as an expense in the period in which the service is received. A liability is recognised to the extent of any unused holiday pay entitlement, which is accrued at the Balance Sheet date and carried forward to future periods. This is measured at the undiscounted salary cost of the future holiday entitlement so accrued at the Balance Sheet date.

Defined contribution pension plans

The company operates two occupational pension schemes, being a defined contribution pension scheme and a personal retirement savings account (PRSA) scheme. Pension benefits are funded over the employees' period of service by way of contributions from the company and from employees. Employer contributions are charged to the Statement of Financial Activities in the year in which they become payable.

Employee benefits are met by payments to a defined contribution pension fund. Contributions are charged to the Statement of Financial Activities in the year in which they fall due. The assets are held separately from those of the Charity in an independently administered fund. Differences between the amounts charged in the Statement of Financial Activities and payments made to pension funds are treated as assets or liabilities.

2.13 Provisions

Provisions are recognised when the Charity has a present legal or constructive obligation as a result of past events; it is probable that an outflow of resources will be required to settle the obligation; and the amount of the obligation can be estimated reliably.

Where there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering the class of obligations as a whole. A provision is recognised even if the likelihood of an outflow with respect to any one item included in the same class of obligations may be small.

2.14 Contingencies

Contingent liabilities, arising as a result of past events, are not recognised when (i) it is not probable that there will be an outflow of resources or that the amount cannot be reliably measured at the reporting date or (ii) when the existence will be confirmed by the occurrence or non-occurrence of uncertain future events not wholly within the company's control. Contingent liabilities are disclosed in the financial statements unless the probability of an outflow of resources is remote. Contingent assets are not recognised. Contingent assets are disclosed in the financial statements when an inflow of economic benefits is probable.

ASTHMA SOCIETY OF IRELAND
NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2022

3. CRITICAL ACCOUNTING JUDGEMENTS AND ESTIMATES

In the application of the Charity's accounting policies, which are described above, the Directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from the other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or the period of the revision and future periods if the revision affects both current and future periods.

a) Critical judgements made in applying the company's accounting policies

Going concern

The Directors have prepared budgets and cash flows for a period of at least twelve months from the date of approval of the financial statements which demonstrate that there is no material uncertainty regarding the company's ability to meet its liabilities as they fall due, and to continue as a going concern.

In making this assessment, the directors have considered the reduced impact of COVID-19 in 2023 under a number of different scenarios as well as the broader economic environment and do not consider the impact will be so significant as to cast doubt on the ability of the organisation to continue in operational existence for the foreseeable future, being 12 months post approval of the financial statements.

The assessment performed is based on a number of key judgements and assumptions including:

- The adoption and implementation of the Financial Resilience and Sustainability Strategy (FRSS) from July 2022 to include diversifying and deepening fundraising across corporate philanthropic donations, income generating programmes (like the Breathe Easy Workplace Wellness programme), and trusts and foundations;
- The implementation of the FRSS to include increased income from public and community fundraising events, a digital Take a Breath campaign, and individual membership income;
- Continued provision of core statutory funding and continued support of statutory funders into 2024;
- The Society's ongoing discipline in streamlining costs across all programmes of work.

The Directors acknowledge that Q1 and Q2 2022 were challenging quarters, but a number of positive developments from Q2 onwards have stabilised the organisation and ultimately position the Society to recover in 2023 and to enter a period of growth in 2024. The Directors are therefore confident in being able to achieve the budgeted results and, in particular, to grow fundraised income

On the basis of the assessments and the underlying assumptions the Directors consider it appropriate to prepare the financial statements on a going concern basis and they do not believe there to be a material uncertainty in respect of same.

b) Key sources of estimation uncertainty

There are no estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.

ASTHMA SOCIETY OF IRELAND
NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2022

4. DONATIONS AND LEGACIES

| | Unrestricted funds 2022 € | Restricted funds 2022 € | Total 2022 € | Total 2021 € |
|--|------------------------------------|----------------------------------|--------------------|--------------------|
| General donations and miscellaneous income | 33,372 | - | 33,372 | 16,416 |
| Regular givers | 15,568 | - | 15,568 | 25,625 |
| Community and events | 22,906 | - | 22,906 | 43,063 |
| Corporate donations | 4,280 | 17,216 | 21,496 | 156,937 |
| Legacies and bequests | 14,100 | - | 14,100 | 20,771 |
| Trust and Foundations | - | - | - | 33,520 |
| | 90,226 | 17,216 | 107,442 | 296,332 |

*The comparatives for 2021 were all classified as unrestricted funds with the exception of income from Corporate Donations of €148,307 and Trust and Foundations of €20,000 which were classified as restricted funds. All income derives from activities in the Republic of Ireland.

5. CHARITABLE ACTIVITIES

Unrestricted funds

| | 2022 € | 2021 € |
|------------------------|-----------|---------------|
| Sale of asthma devices | - | 75 |
| Consultancy fees | - | 13,333 |
| | - | 13,408 |

ASTHMA SOCIETY OF IRELAND

**NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2022**

5. CHARITABLE ACTIVITIES (continued)

Restricted funds

| | | 2022 | 2021 |
|------------------------|-------------------------------|----------------|----------------|
| | | € | € |
| Grantor | Grant Name | | |
| POBAL | Slaintecare Project | 103,282 | 105,274 |
| POBAL | SSNO Programme | 90,500 | 90,000 |
| HSE DNC | Dublin North Central Services | 7,643 | 7,643 |
| HSE Primary Care | Adviceline | 241,700 | 241,700 |
| HSE Under 6's | Welcome Pack U6's | 1,490 | - |
| HSE Stability Funding | | 186,001 | - |
| | | <u>630,616</u> | <u>444,617</u> |
| Total restricted funds | | <u>630,616</u> | <u>444,617</u> |
| Total | | <u>630,616</u> | <u>458,025</u> |

All income from charitable activities derives from activities in the Republic of Ireland.

6. INVESTMENTS

| | 2022 | 2021 |
|-----------------------|-----------|----------|
| | € | € |
| Bank deposit interest | 12 | - |
| | <u>12</u> | <u>-</u> |

Interest income from cash held on deposit is classified as unrestricted income.

7. COST OF RAISING FUNDS

| | 2022 | 2021 |
|-------------------------------------|---------------|---------------|
| | € | € |
| Asthma devices - unrestricted | - | 676 |
| Private Members Draw - unrestricted | 33 | 2,000 |
| Fundraising costs - restricted | 22,041 | 8,738 |
| Fundraising costs - unrestricted | 8,146 | 33,784 |
| | <u>30,220</u> | <u>45,198</u> |

ASTHMA SOCIETY OF IRELAND
NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2022

8. EXPENDITURE ON CHARITABLE ACTIVITIES

Unrestricted funds

| | 2022 | 2021 |
|------------------------------|---------------|----------------|
| | € | € |
| Health promotion | 130 | - |
| Support costs (note 9) | 40,876 | 201,980 |
| Communications and campaigns | - | 18,657 |
| Advocacy and policy | 504 | 16,917 |
| Recruitment | - | 19,849 |
| | 41,510 | 257,403 |

Restricted funds

| | 2022 | 2021 |
|------------------------------|----------------|----------------|
| | € | € |
| Health promotion | 414,137 | 343,442 |
| Support costs (note 9) | 143,326 | 79,473 |
| Communications and campaigns | 28,556 | 135,701 |
| Advocacy and policy | 69,269 | 25,340 |
| | 655,288 | 583,956 |
| Total | 696,798 | 841,359 |

ASTHMA SOCIETY OF IRELAND

**NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2022**

9. SUPPORT COSTS

Allocated to unrestricted funds

| | 2022 | 2021 |
|---|---------------|----------------|
| | € | € |
| Finance and administrative costs | 11,474 | 35,489 |
| Premises costs | 341 | 47,384 |
| General office and programme management costs | 19,766 | 81,987 |
| Human Resources costs | 6,795 | 9,940 |
| Web support | - | - |
| Wages and salaries | - | 14,091 |
| Governance costs (note 10) | 2,500 | 13,089 |
| | 40,876 | 201,980 |

Allocated to restricted funds

| | 2022 | 2021 |
|----------------------------------|----------------|---------------|
| | € | € |
| Finance and administrative costs | 37,460 | 32,507 |
| Premises costs | 43,554 | - |
| General office expenses | 26,207 | 26,960 |
| Human Resources costs | 17,169 | 1,638 |
| Web support | 8,899 | 9,439 |
| Wages and salaries | - | 8,929 |
| Governance costs (note 10) | 10,037 | - |
| | 143,326 | 79,473 |

10. GOVERNANCE COSTS

| | 2022 | 2021 |
|--|---------------|---------------|
| | € | € |
| Auditor's remuneration for statutory audit services (including VAT) - unrestricted | 2,500 | 10,000 |
| Auditor's remuneration for statutory audit services (including VAT) - restricted | 10,037 | - |
| Legal fees | - | 3,089 |
| | 12,537 | 13,089 |

11. NET INCOME / (EXPENDITURE)

Net income / (expenditure) is stated after charging:

| | 2022 | 2021 |
|--|---------------|---------------|
| | € | € |
| Depreciation of tangible fixed assets: | | |
| - owned by the company | 7,065 | 7,569 |
| Auditor's remuneration | 12,537 | 10,000 |
| Pension costs (note 22) | 10,013 | 12,815 |
| | 29,615 | 30,389 |

ASTHMA SOCIETY OF IRELAND

**NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2022**

12. STAFF COSTS

The average number of persons employed by the Charity during the year was as follows (based on head count):

| | 2022 | 2021 |
|-------------------------------|-------------|-------------|
| | No. | No. |
| Fundraising and communication | - | 3 |
| Advocacy | 1 | 1 |
| Patient services | 2 | 4 |
| Nursing team | 7 | 8 |
| Office administration | 2 | 7 |
| | 12 | 23 |

The average number of persons employed by the Charity during the year was as follows (based on full-time equivalent):

| | 2022 | 2021 |
|-------------------------------|-------------|-------------|
| | No. | No. |
| Fundraising and communication | 0.3 | 0.4 |
| Advocacy | 1.0 | 0.5 |
| Patient services | 2.0 | 1.8 |
| Nursing team | 2.4 | 2.8 |
| Office administration | 1.6 | 3.3 |
| | 7.3 | 8.8 |

The average number of persons employed in the tables above excludes the seconded staff from HSE, nursing contractors and community employment scheme participants.

Staff costs were as follows:

| | 2022 | 2021 |
|-------------------------|----------------|----------------|
| | € | € |
| Wages and salaries | 392,625 | 433,828 |
| Employer PRSI | 41,794 | 46,856 |
| Pension costs (note 22) | 10,013 | 12,815 |
| Redundancy costs | - | 19,849 |
| | 444,432 | 513,348 |

The redundancy costs in the prior year relate to an organisational restructure undertaken to reduce overall costs of the Society, on foot of the financial impact of COVID-19.

The Directors do not receive remuneration for their services as members of the Board. Directly incurred expenses are reimbursed, if claimed, and amounted to €Nil (2021: €Nil).

The number of higher paid employees was:

| | 2022 | 2021 |
|-------------------------------|-------------|-------------|
| | No. | No. |
| In the band €80,000 - €90,000 | - | 1 |
| In the band €70,000 - €80,000 | 2 | - |
| In the band €60,000 - €70,000 | - | - |
| | 2 | 1 |

ASTHMA SOCIETY OF IRELAND
NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2022

12. STAFF COST (Continued)

This analysis of salary bands includes basic pay and excludes employer pension and employer PRSI contributions.

The total remuneration of the Chief Executive Officers, which includes employer pension contributions and employer's PRSI, was €121,723 (2021: €131,275). Eilís Ní Chaithnía was appointed as Interim CEO in August 2022 on the resignation of Sarah O'Connor who ceased employment in October 2022.

13. TAXATION

No charge to current or deferred taxation arises as the Charity has been granted charitable status under Sections 207 and 208 of the Taxes Consolidation Act 1997.

14. TANGIBLE FIXED ASSETS

| | Fixtures and fittings € | Computer equipment € | Total € |
|---------------------------------|--|-------------------------------------|--------------------|
| Cost | | | |
| At 1 January 2022 | 28,375 | 4,173 | 32,548 |
| Additions | - | - | - |
| At 31 December 2022 | <u>28,375</u> | <u>4,173</u> | <u>32,548</u> |
| Accumulated depreciation | | | |
| At 1 January 2022 | 7,567 | 2,644 | 10,211 |
| Charge for the year | 5,675 | 1,390 | 7,065 |
| At 31 December 2022 | <u>13,242</u> | <u>4,034</u> | <u>17,276</u> |
| Net book value | | | |
| At 31 December 2022 | <u>15,133</u> | <u>139</u> | <u>15,272</u> |
| At 31 December 2021 | <u>20,808</u> | <u>1,529</u> | <u>22,337</u> |

ASI received four used laptops as donations in kind that have not been valued due to the low value of the devices donated.

ASTHMA SOCIETY OF IRELAND
NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2022

15. STOCKS

| | 2022 | 2021 |
|-------------------------|-------|-------|
| | € | € |
| Stock of asthma devices | 1,212 | 1,212 |

16. DEBTORS

| | 2022 | 2021 |
|-----------------|----------------|---------------|
| | € | € |
| Trade debtors | 186,338 | 15,180 |
| Accrued revenue | - | 47,492 |
| Prepayments | 23,062 | 8,601 |
| | 209,400 | 71,273 |

All debtors are due within one year. All trade debtors are due within the Charity's normal terms. There is no allowance for doubtful debts.

17. CREDITORS: Amounts falling due within one year

| | 2022 | 2021 |
|---------------------------------|----------------|----------------|
| | € | € |
| Trade creditors | 13,923 | 60,795 |
| Taxes and social security costs | 13,673 | 27,139 |
| Other creditors | 18,560 | 18,845 |
| Accruals | 34,533 | 54,063 |
| Deferred income (Note 18) | 367,431 | - |
| | 448,120 | 160,842 |

Trade and other creditors

Trade and other creditors are payable at various dates in the next 12 months in accordance with the suppliers' standard terms.

Taxes and social security costs

Taxes and social security costs are subject to the terms of the relevant legislation. Interest accrues on late payment. No interest was due at the financial year end date.

Accruals

The terms of the accruals are based on underlying contracts.

ASTHMA SOCIETY OF IRELAND

**NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2022**

18. DEFERRED INCOME

Analysis of movement in deferred income

| Current Year | Opening balance | Income received | Released to SOFA | Closing balance |
|---------------------|----------------------------|----------------------------|-----------------------------|----------------------------|
| Restricted | - | 367,431 | - | 367,431 |
| Total | - | 367,431 | - | 367,431 |

Deferred income relates to income from statutory and corporate funders for which attached conditions could not be fulfilled until 2023.

19. STATEMENT OF FUNDS

Current year

| | Unrestricted funds 2022 € | Restricted funds 2022 € | Total funds 2022 € |
|----------------------------|--|--|---------------------------------------|
| At 1 January 2022 | 130,571 | 89,311 | 219,882 |
| Income | 90,238 | 647,832 | 738,070 |
| Expenditure | (49,689) | (677,329) | (727,018) |
| Transfer of funds | 50,416 | (50,416) | - |
| At 31 December 2022 | 221,536 | 9,398 | 230,934 |

Transfer from Restricted Funds to Unrestricted Funds relates to restricted reserves deemed as unrestricted upon a detailed review during 2022.

Prior year

| | Unrestricted funds 2021 € | Restricted funds 2021 € | Total funds 2021 € |
|----------------------------|--|--|---------------------------------------|
| At 1 January 2021 | 283,001 | 69,081 | 352,082 |
| Income | 141,433 | 612,924 | 754,357 |
| Expenditure | (293,863) | (592,694) | (886,557) |
| At 31 December 2021 | 130,571 | 89,311 | 219,882 |

ASTHMA SOCIETY OF IRELAND

**NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2022**

20. FUNDS OF THE CHARITY COMPRISE THE FOLLOWING:

| Current year | Unrestricted funds 2022 € | Restricted funds 2022 € | Total funds 2022 € |
|-------------------------------|--|--|---------------------------------------|
| Tangible fixed assets | 15,272 | - | 15,272 |
| Current assets | 286,953 | 376,829 | 663,782 |
| Creditors due within one year | (80,689) | (367,431) | (448,120) |
| | 221,536 | 9,398 | 230,934 |
| | | | |
| Prior year | Unrestricted funds 2021 € | Restricted funds 2021 € | Total funds 2021 € |
| Tangible fixed assets | 22,337 | - | 22,337 |
| Current assets | 269,076 | 89,311 | 358,387 |
| Creditors due within one year | (160,842) | - | (160,842) |
| | 130,571 | 89,311 | 219,882 |

ASTHMA SOCIETY OF IRELAND

**NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2022**

21. OPERATING LEASE COMMITMENTS

At 31 December the Charity had commitments under non-cancellable operating leases as follows:

| | 2022 | 2021 |
|---|----------------|----------------|
| | € | € |
| In one year or less | 44,280 | 29,239 |
| In more than one year, but not more than five years | 62,730 | 121,770 |
| | 107,101 | 151,009 |

22. PENSION COMMITMENTS

The Charity operates a defined contribution scheme for the benefit of its staff. The assets of the scheme are held separately from those of the Charity in independently administered pension funds. Pension costs for the year amounted to €10,013 (2021: €12,815).

23. FINANCIAL INSTRUMENTS

The carrying amount for each category of financial instruments is as follows:

| | 2022 | 2021 |
|---|----------------|----------------|
| | € | € |
| Financial assets that are debt instruments measured at amortised cost: | | |
| Trade debtors | 186,338 | 15,180 |
| Cash at bank and in hand | 453,170 | 285,902 |
| | 639,508 | 301,082 |
| | | |
| | 2022 | 2021 |
| | € | € |
| Financial liabilities measured at amortised cost | | |
| Trade creditors | 13,923 | 60,795 |
| Other creditors | 18,560 | 18,845 |
| Accruals | 34,533 | 54,063 |
| | 66,916 | 133,703 |

24. CAPITAL COMMITMENTS

There were no capital commitments as at 31 December 2022 (2021: €Nil).

25. COMPANY STATUS

Asthma Society of Ireland is a company limited by guarantee and accordingly does not have a share capital.

Every member of the company undertakes to contribute such amount as may be required not exceeding €5 to the assets of the Charitable Company in the event of its being wound up while he or she is a member.

ASTHMA SOCIETY OF IRELAND

NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2022

26. RELATED PARTY TRANSACTIONS

Related party transactions

Other than as described below, no related party transactions took place during the year ended 31 December 2022.

Key management personnel compensation

The senior employees who have authority and responsibility for planning, directing and controlling the activities of the company are considered to be key management personnel. Total remuneration in respect of these individuals is €173,546 (2021: €172,811).

27. POST BALANCE SHEET EVENTS

There were no material events since the Balance Sheet date.

28. APPROVAL OF FINANCIAL STATEMENTS

The financial statements were approved by the Board on 25 October 2023